MedTrace Logo

Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera

NCT02447016 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-04-27

No results posted yet for this study

Summary

The aim of this prospective, open label study is to check for differences in neuropsychiatric and neurocognitive measurements among patients that will be switched from Atripla to Eviplera among 40 patients.

Conditions

Interventions

DRUG

Tenofovir disoproxil/emtricitabine/rilpivirine

DRUG

Tenofovir disoproxil/emtricitabine/efavirenz

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-12-21
Completion
2016-12-21

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447016 on ClinicalTrials.gov